Visualizing immunotherapy for multiple myeloma worldwide from 2013 to 2023: A bibliometric analysis

Visualizing immunotherapy for multiple myeloma worldwide from 2013 to 2023: A bibliometric analysis

Multiple myeloma (MM) is a malignant, clonal proliferative disease of plasma cells that remains incurable. This paper aims to analyze the current research status and emerging trends in immunotherapy for MM through bibliometric methods, thereby providing valuable references and guidance for future re...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jinqiao Li, Xiaoxia Li, Yueyue Fu, Hongbin Meng, Dan Xu, Wenyi Hou
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	Multiple myeloma immunotherapy bibliometric analysis daratumumab bispecific antibodies CAR-T
Online Access:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2433304
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Extramedullary Multiple Myeloma: Challenges and Opportunities
by: Matthew Ho, et al.
Published: (2025-03-01)

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma
by: Andrée-Anne Pelland, et al.
Published: (2025-04-01)

A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
by: Alfred L. Garfall, et al.
Published: (2025-07-01)

Emerging technology trends in regulatory approvals of cancer immunotherapy drugs by the FDA and EMA
by: Maryam Monajati, et al.
Published: (2024-09-01)

Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma
by: Brandon Tedder, et al.
Published: (2025-07-01)

Bleeding Diathesis Secondary to a Heparin-Like Anticoagulant in a Patient with Multiple Myeloma—A Case Report and Review of Literature
by: Nihar Desai, et al.
Published: (2024-02-01)

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01)

CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
by: Tong Yu, et al.
Published: (2025-02-01)

Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center
by: Shuiqing Xu, et al.
Published: (2024-12-01)

Elranatamab in Heavily Pretreated Triple-class Refractory Multiple Myeloma: A Single-center Experience
by: Ant Uzay
Published: (2025-08-01)

Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis
by: Hua Jiang, et al.
Published: (2024-12-01)

Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens
by: Danilo De Novellis, et al.
Published: (2024-07-01)

Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Treatment Priorities and Novel Therapies
by: Ailawadhi S, et al.
Published: (2025-04-01)

Risk of infections in bispecific antibody therapy for multiple myeloma: a comprehensive review of literature
by: Fahad Alshammari, et al.
Published: (2025-12-01)

Injection site reaction to teclistamab in a patient with multiple myeloma
by: Isabel C. Yoon, BS, et al.
Published: (2025-02-01)

Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
by: Masaud Shah, et al.
Published: (2025-01-01)

Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti‐CD38 Monoclonal Antibodies: A Systematic Review
by: Chia Jie Tan, et al.
Published: (2025-03-01)

Deciphering the bone marrow microenvironment’s role in multiple myeloma immunotherapy resistance
by: Nicolas Thomas Iannozzi, et al.
Published: (2025-07-01)

Treatment of double-refractory multiple myeloma
by: S. V. Semochkin
Published: (2021-09-01)

CD-19-directed immunotherapy resistance mechanisms of B-precursor acute lymphoblastic leukemia
by: E. V. Glukhanyuk, et al.
Published: (2019-01-01)

Daratumumab
by: Vishnu Gopal, et al.
Published: (2020-01-01)

Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement
by: Guido Lancman, et al.
Published: (2024-11-01)

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
by: Hongjie Wang, et al.
Published: (2024-12-01)

Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis
by: Wenze Li, et al.
Published: (2025-04-01)

The hotspots and publication trends in glioblastoma and CAR-T immunotherapy: A bibliometric analysis
by: Zhaoming Song, et al.
Published: (2025-12-01)

Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: A bibliometric analysis from 2004 to 2023
by: Wangshu Li, et al.
Published: (2024-12-01)

Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
by: Barry Paul, et al.
Published: (2025-06-01)

Minimising Toxicity and Maximising Response: T-Cell Engagers for Elderly Patients with Multiple Myeloma
by: Anthony McLoughlin, et al.
Published: (2025-06-01)

Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting
by: Ioannis Ntanasis-Stathopoulos, et al.
Published: (2025-05-01)

Optimal daratumumab-based regimen for patients with newly diagnosed and previously untreated multiple myeloma: systematic review and component network meta-analysis
by: Xiaohua Huang, et al.
Published: (2025-05-01)

CAR-T cell therapy in china: innovations, challenges, and strategic pathways
by: Lihui Yan, et al.
Published: (2025-08-01)

Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients
by: О. I. Ivakhnenko, et al.
Published: (2024-05-01)

Restoring sensitivity to daratumumab with all-transretinoic acid in a patient with daratumumab-refractory multiple myeloma: A case report and review of the literature
by: Noa Biran, et al.
Published: (2025-03-01)

Long-term continuous treatment as a new strategy for relapsed or refractory multiple myeloma
by: S. V. Semochkin
Published: (2020-07-01)

The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service
by: Rakesh Popat, et al.
Published: (2024-12-01)

Worldwide Research Trends on the Immunotherapy-Based Treatment of Ovarian Cancers: A Bibliometric and Visual Analysis
by: Yan L, et al.
Published: (2025-07-01)

Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure
by: Jeries Kort, et al.
Published: (2025-06-01)

Case Report: Reactive T-cell large granular lymphocytes in the bone marrow of a patient with relapsed/refractory multiple myeloma receiving teclistamab
by: Erin A. Dean, et al.
Published: (2025-08-01)

Current advances in bispecific T cell–engaging therapies
by: Emmanuel Owusu Ansah, et al.
Published: (2025-04-01)

Clinical progress of cadonilimab in the treatment of malignant tumor
by: ZHANG Xiaoqing, et al.
Published: (2025-06-01)